Stock KZIA KAZIA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kazia Therapeutics Limited

Equities

KZIA

US48669G1058

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-06-03 pm EDT 		5-day change 1st Jan Change
0.2699 USD +3.81% Intraday chart for Kazia Therapeutics Limited -3.37% -38.59%
May. 01 Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients CI
Apr. 19 Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 19.36 23.12 46.48 170.5 84.5 39.72
Enterprise Value (EV) 1 13.4 17.69 37.71 142.9 77.14 36.27
P/E ratio -3.2 x -2.08 x -2.88 x -18.4 x -3.27 x -1.55 x
Yield - - - - - -
Capitalization / Revenue 6.44 x 15 x 47 x 11.2 x 8,450 x 71,562 x
EV / Revenue 4.46 x 11.5 x 38.2 x 9.41 x 7,714 x 65,355 x
EV / EBITDA -1.24 x -2.32 x -3.39 x -27.9 x -3.37 x -1.63 x
EV / FCF -2.33 x -3.63 x -12.9 x 113 x -5.51 x -2.48 x
FCF Yield -43% -27.5% -7.73% 0.88% -18.1% -40.3%
Price to Book 1.01 x 1.63 x 3.29 x 4.59 x 4.53 x 3.3 x
Nbr of stocks (in thousands) 4,841 6,217 9,460 12,962 13,876 22,803
Reference price 2 3.999 3.720 4.913 13.15 6.090 1.742
Announcement Date 8/29/18 8/28/19 8/26/20 8/25/21 8/28/22 8/31/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Junio 2018 2019 2020 2021 2022 2023
Net sales 1 3.004 1.54 0.9881 15.18 0.01 0.000555
EBITDA 1 -10.81 -7.612 -11.11 -5.113 -22.91 -22.28
EBIT 1 -12.36 -8.696 -12.19 -6.378 -24.87 -24.15
Operating Margin -411.41% -564.64% -1,234.06% -42.01% -248,657.02% -4,350,725.59%
Earnings before Tax (EBT) 1 -6.344 -10.57 -12.77 -8.906 -25.02 -20.74
Net income 1 -6.039 -10.27 -12.47 -8.422 -24.65 -20.47
Net margin -201.03% -666.85% -1,261.75% -55.47% -246,478.15% -3,687,419.82%
EPS 2 -1.248 -1.786 -1.707 -0.7160 -1.861 -1.123
Free Cash Flow 1 -5.757 -4.868 -2.917 1.26 -14 -14.63
FCF margin -191.64% -316.1% -295.19% 8.3% -139,980.1% -2,635,182.88%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/29/18 8/28/19 8/26/20 8/25/21 8/28/22 8/31/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2
Net sales 1 - 0.3693 0.032 15.18 0.027 0.00011 0.00014 0.023
EBITDA - - - - - - - -
EBIT 1 - -6.769 -6.513 0.06 -13.26 -11.68 - -10.49
Operating Margin - -1,832.75% -20,358.42% 0.4% -49,218.07% -10,615,918.18% - -45,657.9%
Earnings before Tax (EBT) - - - - - -11.68 - -
Net income 1 -5.881 - - - - -11.63 -13.59 -6.879
Net margin - - - - - -10,568,554.55% -9,704,307.14% -29,948.41%
EPS - - - - - -0.8746 - -
Dividend per Share - - - - - - - -
Announcement Date 2/19/20 8/26/20 2/24/21 8/25/21 2/23/22 8/28/22 2/28/23 8/31/23
1AUD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 5.96 5.43 8.76 27.6 7.36 3.44
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -5.76 -4.87 -2.92 1.26 -14 -14.6
ROE (net income / shareholders' equity) -27.1% -61.4% -88% -32.4% -87.3% -135%
ROA (Net income/ Total Assets) -24.1% -22% -34.5% -9.82% -33.4% -47.2%
Assets 1 25.05 46.63 36.19 85.72 73.78 43.38
Book Value Per Share 2 3.970 2.280 1.490 2.870 1.340 0.5300
Cash Flow per Share 2 1.230 0.8700 0.9300 2.090 0.5300 0.2300
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 8/29/18 8/28/19 8/26/20 8/25/21 8/28/22 8/31/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
KAZIA THERAPEUTICS LIMITED Stock Kazia Therapeutics Limited
-38.59% 7.11M
MODERNA, INC. Stock Moderna, Inc.
+48.64% 56.65B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.44% 39.44B
LONZA GROUP AG Stock Lonza Group AG
+40.77% 39.03B
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.86B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.28% 26.75B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.40% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.96% 12.28B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.64% 12.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.04% 12.04B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. KZIA Stock
  4. Financials Kazia Therapeutics Limited